Abrocitinib for skin and hair loss in Down syndrome
Treatments studied
Part of Brain & nervous system, Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests if the pill abrocitinib can help people with Down syndrome who have atopic dermatitis (eczema) or alopecia areata (patchy hair loss). The goal is to see if it improves their skin or hair with manageable side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have Down syndrome (Trisomy 21 or a translocation type).
- You are at least 12 years old.
- You have had eczema covering at least 7% of your body for 6 months or more, OR you have had hair loss covering at least 25% of your scalp for 6 months or more.
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use effective birth control during the study and for 28 days after.
- You have not used certain strong skin or immune treatments (like steroids, injections, or other JAK inhibitor pills) within the past few weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well abrocitinib (a daily pill) works for people with moderate to severe eczema who have already tried biologic medicines and didn't get enough relief. It aims to see if this treatment can help you better manage your eczema.
This study tests a daily pill, abrocitinib, to see if it safely reduces severe eczema (atopic dermatitis) in children aged 2 to under 6 years. It may help when creams or other treatments haven't worked well enough.
This study tests the long-term safety and effectiveness of abrocitinib (Cibinqo) for children aged 6 to 12 with moderate to severe eczema that hasn't improved with creams. It may help their skin clear and reduce itching.
This study tests how well abrocitinib (a prescription medicine) works for adults with moderate to severe atopic dermatitis (atopic eczema). You may join if you meet the study’s health and consent requirements and your doctor believes abrocitinib is an appropriate option for you.
This study tests whether gradually lowering the dose of abrocitinib can keep your eczema under control while reducing side effects. It is for people with moderate-to-severe eczema who have already been on abrocitinib 200 mg daily for at least 3 months and whose skin is currently well controlled.
This study tests an oral tablet called upadacitinib for people with severe alopecia areata who have lost at least half of their scalp hair. It aims to see if the drug can safely help hair regrow.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.